Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin.
- Author:
Zhen JIN
1
;
Ting GUAN
;
Shourou LI
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; pharmacology; Blotting, Northern; Blotting, Western; Cell Cycle; physiology; Cell Division; drug effects; genetics; Cisplatin; pharmacology; DNA, Complementary; genetics; Dose-Response Relationship, Drug; Female; Genotype; Humans; Ovarian Neoplasms; drug therapy; genetics; pathology; Plasmids; genetics; RNA, Messenger; genetics; metabolism; Time Factors; Transfection; Tumor Cells, Cultured; drug effects; Tumor Suppressor Protein p53; genetics; metabolism; physiology
- From: Chinese Journal of Medical Genetics 2002;19(3):218-220
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the effect of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin.
METHODSRecombinant eukaryotic expression vector pcDNA3 containing full-length human wild-type p53 cDNA was introduced by lipofectamine-mediated gene transfection into SKOV-3 cultured cells which were acted on by cisplatin of different concentrations. The chemotherapy sensitivity of tumor cells with different-status p53 was observed.
RESULTSThe inhibitive rate of formation of clones after p53 cDNA transfection was 56.4% compared with the untransfected one. The formation of clones decreased by 76.2% and 84.1% respectively after being acted on by 0.5 ug/ml cisplatin for 24 hours and 48 hours respectively. The formation of clones decreased by 89.5% and 93.7% respectively after being acted on by 1 ug/ml cisplatin for 24 hours and 48 hours respectively. After the introduction of p53 cDNA, the S phase and the ratio of G(2)/M phase of tumor cells decreased, and the ratio of G(1)/G(0) phase increased. The introduction of p53 gene into cells led to cell cycle arrest in G(1) phase.
CONCLUSIONThe exogenous introduction of wild-type p53 cDNA into ovarian cancer SKOV-3 cells increased the chemotherapy sensitivity to cisplatin.